PMC9869906_01
Pathological images of the patient in September 2012: HE, 100x (A); ER, 200x (B); PR, 200x (C); CerbB-2, 200x (D); Ki67, 200x (E); CK5/6, 200x (F); P40, 200x (G); P63, 200x (H); Vimentin, 200x (I); E-cadherin, 200x (J). Pathological images of the patient in July 2014: HE, 200x (K); FISH (L).
BCTT-15-39-g0002.jpg
PMC9869906_01_BCTT-15-39-g0002.jpg
f0002
Pathology after the operation revealed that the mass was squamous cell carcinoma and partial ductal carcinoma in situ (Figure 2A), with noninvolvement of the axillary lymph nodes. Immunohistochemical results were negative for ER, PR and HER-2 (Figure 2B-, respectively), and the Ki67 index was 60% (Figure 2E). In addition, CK5/6, P40, P63, Vimentin and E-cadherin were positive (Figure 2F-, respectively). II (Figure 2K). Immunohistochemistry revealed the same results as previously found except HER2 was 2+. Hence, fluorescence in situ hybridization was performed and showed that HER2 was overexpressed (Figure 2L).
CT images of the patient in June 2013 (A); September 2013 (B); March 2014 (C); July 2014 (D); November 2014 (E); and March 2021 (F).
BCTT-15-39-g0003.jpg
PMC9869906_01_BCTT-15-39-g0003.jpg
f0003
CT revealed a soft tissue mass in the right axillary region (Figure 3A), which was approximately 3 cm in size. F) due to the obvious enlargement of the right axillary mass (Figure 3B). From October 17, 2013, to June 7, 2014, the patient completed seven cycles of chemotherapy (gemcitabine, 1200 mg, Day 1 and Day 8). CT images showed that the right breast mass, although reduced, was still present (Figure 3C).  In July 2014, the chemotherapy regimen for the patient was changed to one cycle of chemotherapy (paclitaxel liposome, 120 mg, qw, and capecitabine, 1500mg, bid, Day 1 to Day 14) due to the gradually increasing lump in the right armpit (Figure 3D), but the mass did not shrink significantly. Since then, no signs of recurrence have been found (Figure 3Eand Figure 3).